Tissium Raises €60M for Sutureless Nerve Repair: Funding, FDA Milestones, and Next Steps

An undisclosed U.S.-based family-owned institutional investor led the Series D2, according to multiple sources. Additional participants included new family offices, high-net-worth individuals, and existing backers such as Mérieux Développement and Cathay (Cathay Health previously led Tissium's €50 million Series C in 2024).

Total Equity Raised: €200M to Date

With this Series D2, Tissium has raised €200 million in total equity funding across all rounds since its founding in 2013. A Tissium spokesperson confirmed the figure to MedTech Dive. (Earlier platform reports citing totals of $202M – $214M likely include debt or non-equity instruments and are not inconsistent with the €200M figure.)

Biomorphic Programmable Polymers: How the Technology Works

Tissium's core platform is a proprietary class of biomorphic programmable polymers — flexible, biocompatible materials that conform to surrounding tissue and bond to it after being activated by blue light (the TISSIUM Light system). The technology was originally developed at MIT in the labs of Bob Langer and Jeff Karp.

The polymer's building blocks—based on naturally occurring compounds such as glycerol and sebacic acid—can be adjusted to match the mechanical and biological requirements of different tissues. A viscous pre-polymer is applied during surgery, then activated with light to form a strong, flexible bond.

FDA Approvals and Regulatory Progress

Peripheral Nerve Repair (COAPTIUM CONNECT)

In June 2025, the FDA granted De Novo marketing authorization for the COAPTIUM CONNECT with TISSIUM Light system, making it the first and only FDA-authorized atraumatic sutureless solution for peripheral nerve coaptation. The first commercial U.S. use occurred in November 2025 at Cooper University Hospital (Camden, NJ), performed by plastic surgeon Dr. Michael Franco.

First-in-human clinical data were published in the Journal of Hand Surgery Global Online in March 2026.

Hernia Repair (ECLIPSIUM)

Tissium does not yet have an FDA-cleared hernia device. In September 2025, the company received an Investigational Device Exemption (IDE) from the FDA for ECLIPSIUM, its solution for ventral hernia repair, and plans to initiate a U.S. clinical trial. (Note: The Phasix ST Umbilical Hernia Patch (K243241) cleared in February 2025 is a Bard/Davol product, not a Tissium product.)

Vascular Sealant

The FDA also approved Tissium's Investigational Device Exemption application for its vascular sealant, designed to achieve haemostasis after peripheral vascular surgeries.

Planned Use of Funds

Tissium intends to deploy the capital for :

• U.S. commercial rollout of the COAPTIUM CONNECT nerve repair system
• Clinical trials to support new indications (hernia repair, cardiovascular sealing, and other soft-tissue applications)
• Platform and pipeline expansion into additional tissue-repair indications

The financing follows a transformative year for the company: its first FDA product authorization, entry into the U.S. market, and continued pipeline progress.

Bottom Line

Tissium's €60M financing package—backed by an undisclosed U.S. family office, existing investors Mérieux Développement and Cathay, and the European Investment Bank—positions the company to scale its sutureless nerve repair platform while advancing clinical trials in hernia and vascular repair. With €200M in total equity raised and one FDA-authorized product already in commercial use, the company represents one of the most advanced bet on polymer-based tissue reconstruction.